INBX · Inhibrx Biosciences, Inc.
$93.38
-3.83% last session
End-of-day data · close of 2026-10-23
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-10.7
Dividend yield
0.0%
Beta
3.82
Avg volume
0M
Employees
0K
Daily Change %
-3.83%
5 Days Change
4.00%
10 Days Change
9.52%
30 Days Change
-6.99%
60 Days Change
-23.91%
Month to Day Change
-4.65%
Year to Day Change
18.20%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — INBX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-24
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-24 | HC Wainwright & Co. | Initiates | Buy | $0.00 → $245 |
| 2026-04-08 | Stifel | Initiates | Buy | $0.00 → $150 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 45 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 10.0% below the 50-day MA ($103.80).
- bullish: Price vs 200-day MA: Trading 1.5% above the 200-day MA ($91.99).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.86) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($28.36) and high ($141.84).
INBX Price Chart
Loading chart for INBX…
Fundamentals
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.